Demographic data and baseline characteristics by percentiles of change from baseline of PACT−Q2 convenience score at visit 2 and their standardised differences
| Eligible patients | 0–20th percentile (poor responders) | 21st–79th percentile (normal responders) | >80th percentile (super responders) | Standardised difference: poor vs super responders |
| 70 | 183 | 63 | ||
| Sex | ||||
| Female | 21 (30%) | 59 (32.24%) | 23 (36.51%) | −0.1385* |
| Male | 49 (70%) | 124 (67.76%) | 40 (63.49%) | 0.1385 |
| Age (years) | ||||
| Mean±SD | 69.3±8.6 | 69.9±8.9 | 67.9±9.0 | 0.1614* |
| <65 years | 18 (25.71%) | 44 (24.04%) | 17 (26.98%) | 0.0288 |
| >=65 to <75 years | 29 (41.43%) | 72 (39.34%) | 31 (49.21%) | −0.1567* |
| >=75 years | 23 (32.86%) | 67 (36.61%) | 15 (23.81%) | 0.2018* |
| CHA2DS2-VASc stroke risk score | ||||
| Mean±SD | 3.1±1.5 | 3.1±1.5 | 3±1.1 | 0.0857 |
| Low risk (score=0) | 1 (1.43%) | 1 (0.55%) | 0 | 0.1703* |
| Intermediate risk (score=1) | 8 (11.43%) | 28 (15.30%) | 3 (4.76%) | 0.2463 |
| High risk (score>=2) | 61 (87.14%) | 154 (84.15%) | 60 (95.24%) | −0.2886* |
| HAS-BLED bleeding risk score | ||||
| Mean±SD | 1.8±1.0 | |||
| Low risk (score<3) | 53 (75.71%) | 143 (78.14%) | 50 (79.37%) | −0.0876 |
| High risk (score>=3) | 17 (24.29%) | 40 (21.86%) | 13 (20.63%) | 0.0876 |
| Creatinine clearance (mL/min) | ||||
| Mean±SD | 67.7±23.4 | 69.5±20.6 | 72.1±25.9 | −0.1759* |
| <50 mL/min | 13 (18.57%) | 20 (10.93%) | 10 (15.87%) | 0.0715 |
| 50 to <80 mL/min | 24 (34.29%) | 59 (32.24%) | 23 (36.51%) | −0.0465 |
| >=80 mL/min | 15 (21.43%) | 33 (18.03%) | 12 (19.05%) | 0.0593 |
| Not available | 18 (25.71%) | 71 (38.80%) | 18 (28.57%) | −0.0643 |
| Presence of at least one concomitant disease | 47 (67.14%) | 146 (79.78%) | 40 (63.49%) | 0.0768 |
| Concomitant diseases† | ||||
| Hypertension | 32 (45.71%) | 78 (42.62%) | 23 (36.51%) | 0.1879* |
| Hyperlipidaemia | 17 (24.29%) | 70 (38.25%) | 18 (28.57%) | −0.0973 |
| DM (T2 or T1) | 12 (17.14%) | 36 (19.67%) | 9 (14.29%) | 0.0786 |
| CHF | 15 (21.43%) | 33 (18.03%) | 12 (19.05%) | 0.0593 |
| Stroke | 7 (10.00%) | 19 (10.38%) | 3 (4.76%) | 0.2014* |
| Comorbidities, group 1 | ||||
| Patients with malignancy | 3 (4.29%) | 10 (5.46%) | 4 (6.35%) | −0.0921 |
| Patients with no malignancy | 67 (95.71%) | 173 (94.54%) | 59 (93.65%) | 0.0921 |
| Comorbidities, group 2 | ||||
| Patients with GI disease | 8 (11.43%) | 21 (11.48%) | 4 (6.35%) | 0.1792 |
| Patients with no GI disease | 62 (88.57%) | 162 (88.52%) | 59 (93.65%) | −0.1792* |
*Significant differences between the super-responders and the poor responders.
†Most frequent five are listed.
CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years (double score), diabetes, stroke or transient ischemic attack (TIA; double score), vascular disease, age 65–74 years, sex class; CHF, congestive heart failure; DM, diabetes mellitus; GI, gastrointestinal; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly (> 65 years), drugs/alcohol concomitantly.